Zanubrutinib in Primary Cold Agglutinin Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 26, 2024

Primary Completion Date

November 1, 2027

Study Completion Date

November 1, 2028

Conditions
Lymphoma
Interventions
DRUG

Zanubrutinib Oral Capsule

36 cycles (1 cycle is 28 days)

Trial Locations (10)

Unknown

NOT_YET_RECRUITING

UZ leuven, Leuven

RECRUITING

AZ Delta, Roeselare

NOT_YET_RECRUITING

Rigshospitalet, Copenhagen

NOT_YET_RECRUITING

Odense University Hospital, Odense

RECRUITING

Amsterdan UMC ( location AMC), Amsterdam

NOT_YET_RECRUITING

UMCG, Groningen

NOT_YET_RECRUITING

Erasusmc, Rotterdam

NOT_YET_RECRUITING

Haukeland University Hospital Bergen, Bergen

NOT_YET_RECRUITING

Oslo University Hospital, Oslo

NOT_YET_RECRUITING

st. Olavs Hospital, Trondheim

All Listed Sponsors
lead

Stichting Hemato-Oncologie voor Volwassenen Nederland

OTHER